Bedford Laboratories To Begin Shipping Deferoxamine
Bedford, OH – Bedford Laboratories, a division of Ben Venue Laboratories Inc., announced FDA approval to begin shipping Deferoxamine Mesylate for Injection USP. This product is AP rated and is equivalent to Desferal by Novartis. Deferoxamine is an iron chelating agent indicated for the treatment of acute iron intoxication and chronic iron overload due to transfusion-dependent anemias.
"As part of our continuing strategy to expand our product portfolio, Bedford Laboratories is pleased to be offering such an important product," said David Gaugh, Vice President and General Manager of Bedford Laboratories.
Bedford Laboratories will supply Deferoxamine Mesylate for Injection USP as a sterile lyophilized powder in two single dose presentations: 500 mg and 2 gram.
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
Boehringer Ingelheim Corporation Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of US $13.3b (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business, segment Prescription Medicines, on research and development.
SOURCE: Bedford Laboratories